TaiwanJ Pharmaceuticals Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include live… Read more
TaiwanJ Pharmaceuticals Co., Ltd. (6549) - Total Liabilities
Latest total liabilities as of June 2025: NT$5.59 Million TWD
Based on the latest financial reports, TaiwanJ Pharmaceuticals Co., Ltd. (6549) has total liabilities worth NT$5.59 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TaiwanJ Pharmaceuticals Co., Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how TaiwanJ Pharmaceuticals Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TaiwanJ Pharmaceuticals Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of TaiwanJ Pharmaceuticals Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Star Media Group Bhd
KLSE:6084
|
Malaysia | RM58.62 Million |
|
4C Group AB
ST:4C
|
Sweden | Skr248.63 Million |
|
Maxeon Solar Technologies Ltd
NASDAQ:MAXN
|
USA | $507.96 Million |
|
The Caldwell Partners International Inc
OTCQX:CWLPF
|
USA | $42.62 Million |
|
Sievi Capital Plc
F:WE3
|
Germany | €228.30 Million |
|
Orvana Minerals Corp
PINK:ORVMF
|
USA | $165.46 Million |
|
NSE SA
PA:ALNSE
|
France | €53.41 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down TaiwanJ Pharmaceuticals Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TaiwanJ Pharmaceuticals Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TaiwanJ Pharmaceuticals Co., Ltd. (2019–2024)
The table below shows the annual total liabilities of TaiwanJ Pharmaceuticals Co., Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$5.71 Million | -13.67% |
| 2023-12-31 | NT$6.62 Million | -19.14% |
| 2022-12-31 | NT$8.19 Million | +19.47% |
| 2021-12-31 | NT$6.85 Million | -5.87% |
| 2020-12-31 | NT$7.28 Million | -11.38% |
| 2019-12-31 | NT$8.21 Million | -- |